Navigation Links
Compound developed by scientists protects heart cells during and after attack
Date:2/7/2013

JUPITER, FL, February 7, 2013 Using two different compounds they developed, scientists from the Florida campus of The Scripps Research Institute (TSRI) have been able to show in animal models that inhibiting a specific enzyme protects heart cells and surrounding tissue against serious damage from heart attacks. The compounds also protect against additional injury from restored blood flow after an attack, a process known as reperfusion.

The study, which was led by Philip LoGrasso, a professor and senior scientific director of discovery biology at Scripps Florida, appears in the February 8, 2013 print edition of The Journal of Biological Chemistry.

A heart attack severely restricts blood supply, starving heart cells and surrounding tissue of oxygen, which can cause enormous damage in relatively little timesometimes in just a few minutes. Known as an ischemic cascade, this drop-off of oxygen results in a sudden crush of metabolic waste that damages cell membranes as well as the mitochondria, a part of the cell that generates chemical energy and is involved in cell growth and death.

Unfortunately, restoring blood flow adds significantly to the damage, a serious medical issue when it comes to treating major ischemic events such as heart attack and stroke. Reperfusion re-invigorates production of free radicals and reactive oxygen species that attack and damage cells, exacerbating inflammation, turning loose white blood cells to attack otherwise salvageable cells and maybe even inducing potentially fatal cardiac arrhythmias.

The new study found that inhibiting the enzyme, c-jun-N-terminal kinase (JNK), pronounced "junk," protected against ischemic/reperfusion injury in rats, reducing the total volume of tissue death by as much as 34 percent. It also significantly reduced levels of reactive oxygen species and mitochondrial dysfunction.

In earlier studies, TSRI scientists found that JNK migrates to the mitochondria upon oxidative stress. That migration, coupled with JNK activation, they found, is associated with a number of serious health issues, including liver damage, neuronal cell death, stroke and heart attack. The peptide and small molecule inhibitor (SR3306) developed by LoGrasso and his colleagues blocks those harmful effects, thereby reducing programmed cell death four-fold.

"This is the same story," said LoGrasso. "These just happen to be heart cells, but we know that oxidative stress kills cells, and JNK inhibition protects against this stress. Blocking the translocation of JNK to the mitochondria is essential for stopping this killing cascade and may be an effective treatment for damage done to heart cells during an ischemic/reperfusion event."

In addition, LoGrasso said, biomarkers that rise during a heart attack shrink in the presence of JNK inhibition, a clear indication that blocking JNK reduces the severity of the infarction.


'/>"/>

Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute
Source:Eurekalert  

Related medicine news :

1. TriMix Laboratories Announces New TriMix-gel Partnership with US Compounding
2. Scripps Florida scientists develop new compound that reverses fatty liver disease
3. Women’s Excellence in Bladder Control Partners with University Compounding Pharmacy in Troy, MI to Help Women with Chronic Pelvic Pain Conditions
4. Compounding Pharmacists Oppose Greater U.S. Oversight
5. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
6. Second Compounding Pharmacy Shut Down in Massachusetts
7. Compounds activate key cancer enzyme to interfere with tumor formation
8. Green tea compound shows promise for tackling cancer
9. Red wine compound could help seniors walk away from mobility problems
10. Breast-Milk Compound May Shield Babies From HIV
11. Natural Sciences Repository Publishes Chromatography and Acidic Compounds Resources
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Compound developed by scientists protects heart cells during and after attack
(Date:5/23/2017)... ... ... Allegheny Health Network and the Alexis Joy D’Achille Foundation ... at West Penn Hospital , a unique facility that will offer the most ... Construction of the Center is underway with a scheduled opening in the fall of ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability of ... Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to ... ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: Walter Schindler, ... this month as a Guest Speaker and Contributor to a weeklong series of classes, ... Purpose. , Walter Schindler and SAIL Capital have received ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. Allen Huang and Jeffrey ... in Las Vegas, NV, and the importance of treating it immediately. They are ... care for peri-implantitis, with or without a referral. As experienced periodontists and implant ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients from Charleston, SC, are now ... practicing in Mt. Pleasant, SC, with or without a referral. A full mouth reconstruction ... missing teeth in Charleston, SC. Those who suffer from gum disease, misaligned ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed its acquisition ... care service center company based in Chantilly, ... management programs for leading pharmaceutical manufacturers and health care ... will join Envoy Health Management, LLC , as ... firms, and other service companies. Together, WRB and EnvoyHealth ...
(Date:5/4/2017)...  A recent study published in the American ... as a means of disinfection anesthesia workstations ... on anesthesia workstations. In the study, UVC disinfection ... equipment surfaces contaminated with three (3) organisms commonly ... further validates the body of literature supporting Tru-D," ...
(Date:5/4/2017)... 4, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... "Company"), today announced that the Company,s first quarter 2017 ... Thursday, May 11, 2017, and that the Company will ... p.m. PT that afternoon. Management will provide an overview ...
Breaking Medicine Technology: